BioVie KOL Webinar on Neuroinflammation and Insulin Resistance and New Treatment Approaches for Alzheimer’s Disease (AD)
|DATE:||October 26, 2021|
|TIME:||12:00 AM EDT|
About The Event
The webinar will feature presentations by Key Opinion Leaders (KOLs) Jefferson Kinney, Ph.D. (University of Nevada, Las Vegas) who will discuss the basis of inflammation as a central mechanism in Alzheimer’s disease, and Karl Herrup, Ph.D. (University of Pittsburgh School of Medicine) who will discuss the importance of age-related hyperinsulinemia and brain insulin resistance in neurodegeneration.
BioVie’s management team will also discuss NE3107 for the treatment of Alzheimer’s disease. NE3107’s mechanism acts on both the fundamental inflammatory signaling pathways and the consequent insulin resistance that are the root causes of Alzheimer’s and other neurodegenerative diseases. BioVie recently announced that the Company has enrolled the first patient into the NM101 Phase III clinical study testing NE3107 for the treatment of Alzheimer’s Disease (AD). The NM101 study is a potentially pivotal Phase 3, randomized, double-blind, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate AD.
A live Q&A session will follow the formal presentations.